Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT02637531
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UCSD, San Diego, California, United States
🇺🇸UCLA, Santa Monica, California, United States
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 17
- Registration Number
- NCT02635061
- Locations
- 🇺🇸
Local Institution - 350, Boston, Massachusetts, United States
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Fondazione Melanoma Onlus
- Target Recruit Count
- 251
- Registration Number
- NCT02631447
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
🇮🇹IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 32
- Registration Number
- NCT02626065
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 52
- Registration Number
- NCT02626962
- Locations
- 🇪🇸
H. C. U. de Valladolid, Valladolid, Spain
🇪🇸H. U. Virgen de la Victoria, Malaga, Spain
🇪🇸Hospital La Paz, Madrid, Spain
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 7
- Registration Number
- NCT02621515
- Locations
- 🇳🇱
Dutch Cancer Institute/ A v. Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
- Conditions
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 560
- Registration Number
- NCT02617589
- Locations
- 🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
🇺🇸Local Institution - 0090, Chattanooga, Tennessee, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT02612779
- Locations
- 🇺🇸
Bay Hematology Oncology, Easton, Maryland, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 504
- Registration Number
- NCT02613507
- Locations
- 🇨🇳
Local Institution - 0051, Beijing, Beijing, China
🇨🇳Local Institution - 0007, Beijing, Beijing, China
🇷🇺Local Institution - 0039, Chelyabinsk, Russian Federation
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT02599649
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.